Abstract. Lung cancer is commonly associated with multiorgan metastasis, and the bone is a frequent metastatic site for lung cancer. However, the molecular mechanism of organspecific metastasis remains poorly understood. To elucidate this issue, we analyzed in this study genome-wide gene expression profiles of 15 metastatic lesions from three organs (bone, lung and liver) in a mouse model with multi-organ metastasis properties of human non-small cell lung cancer cells (ACC-LC319/ bone2), using a combination of laser-microbeam microdissection and DNA microarrays. We identified 299 genes that could potentially be involved in the organ-selective nature of lung cancer metastasis. Among them, 77 were bone-specifically expressed elements, including genes involved in cell adhesion, cytoskeleton/cell motility, extracellular matrix remodeling and cell-cell signaling as well as genes already known to be involved in the bone metastasis of breast cancers. Quantitative RT-PCR confirmed the specific upregulation of eight genes in bone metastasis tumors, suggesting that these genes may be involved in bone metastasis. Our findings should be helpful for a better understanding of the molecular aspects of the metastatic process in different organs, and could lead to molecular target-based anticancer drugs and prevention of metastasis, especially bone metastasis.
Introduction
Lung cancer is the leading cause of mortality worldwide and its incidence is rising in many countries (1) . The high mortality of this disease is predominantly due to the difficulty of early diagnosis and the highly metastatic potential of lung cancer. In many cases, metastases to multiple organs have already developed by the time of diagnosis (2) (3) (4) . In particular, ~30-40% of patients with advanced lung cancer will develop bone metastases in the course of their disease, resulting in a significant negative impact on both morbidity and survival (3) (4) (5) . Currently no curative therapy exists for bone metastasis, and clinical management is generally palliative (3, 6, 7) . Hence, the prevention and treatment of bone metastases are clinically vital.
Most treatments for lung cancer bone metastases are proposed based on targeting the osteoclast-activating pathway, which is the key deregulation in bone metastasis in many types of cancers (3, (6) (7) (8) (9) (10) . However, the cancer cells metastasizing to the bone may express certain features that mediate and favor their colonization in the bone, as well as disrupt the normal balance of bone formation and bone resorption (6, 7, 9) . During such tumor progression, cancer cells are thought to acquire several genetic alterations. We believe that identifying such molecular changes in the cancer cells themselves can probably help to solve, at least in part, bone metastases in lung cancer. In order to understand the molecular mechanism of metastasis, especially bone metastasis, and to establish a moleculartargeted therapy, the development of a clinically relevant animal model is essential. A complex approach of animal models and transcriptomic analyses can provide a considerable amount of information for characterizing the nature of individual cancers; the promise of such information lies in its potential for improving clinical strategies for treatment of cancer through development of novel drugs (5, 11, 12) . With that goal in mind, we performed gene expression profiling in a multiple-organ metastasis mouse model of human small cell lung cancer cells (SCLC), and identified a dozen candidate genes that may affect or determine organ specificity of the metastatic cells, as well as genes involved metastatic processes in different microenvironments (11) .
To investigate the molecular bases of organ-specific metastasis, especially the bone, we previously established a multiple-organ metastasis mouse model of human non-small
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by genome-wide gene expression profile analysis of non-small cell lung cancer in mice cell lung cancer cells (NSCLC; ACC-LC319/bone2), and performed transcriptomic analysis of in vivo metastatic tissues to propose new profiles of lung cancer metastases to multiple organs, including bone metastases. Here, we showed organspecific gene expression profiles of metastases in the bone, lung and liver, and selectively validated the findings of eight genes in the 'bone profile'. The data from these experiments not only should provide important information about the organ-tropism nature of NSCLC-metastasis, but also be valuable for identifying candidate genes whose products might serve as molecular targets for treatment of NSCLC metastasis, especially bone metastasis.
Materials and methods

Cell lines.
A human lung adenocarcinoma cell line ACC-LC-319/bone2 with a high bone metastasis ability was established as described previously (13) . We confirmed no Mycoplasma contamination in cultures of the cell line used in vitro and in vivo using PCR Mycoplasma Detection set (Takara, Shiga, Japan).
No abnormalities were observed on the cellular morphology of this cell line either at high or low densities of cultures by microscopy. Cells were cultured in RPMI-1640 medium (Invitrogen, Carlsbad, CA), supplemented with 10% fetal bovine serum (Nichirei Biosciences, Tokyo, Japan), antibiotic-antimycotic mixture (Invitrogen), and incubated at 37˚C in a humidified atmosphere containing 5% of CO 2 .
In vivo mouse model. Seven-week-old male SCID mice (C.B-17/ Icr-scid/scidJc1, CLEA Company, Japan) were depleted of NK-cells and intravenously inoculated with ACC-LC319/bone2 cells as described previously (13) . The mice were sacrificed on the 34th day after tumor cell inoculation, and the lungs, livers and hind limp bones containing macroscopic lesions were embedded in Tissue Tek OCT medium (Sakura, Tokyo, Japan), and snap frozen in liquid nitrogen and stored at -80˚C until use. All the experiments in mice were performed under the Guidelines for Animal Welfare in The University of Tokushima, Tokushima.
Laser microbeam microdissection. The frozen tissues were cut into 8-10 µm sections and applied to PEN-membrane slide (Leica, Herborn, Germany), and then stained with hematoxylin and eosin (H&E) for histological examination. The stained tissues were observed microscopically; 15 metastatic lesions (5 bones, 5 lungs and 5 livers) were selectively obtained for laser-microbeam microdissection using PALM Microbeam system (Carl Zeiss, Jena, Germany) according to the manufacturer's protocols. To avoid cross-hybridization of normal mouse mRNA on DNA microarray as described below, we microdissected normal mouse cells in the surrounding regions far from the metastatic lesions of each of the three organs (bone, lung and liver).
RNA extraction, RNA amplification and DNA microarray. Total RNA from each microdissected tissue and the in vitro cell line ACC-LC319/bone2 were extracted using RNeasy mini kit (Qiagen, Valencia, CA, USA) according to the manufacturer's protocol. The purity and integrity of RNA were assessed by NanoDrop system (Thermo Scientific, Wilmington, Delaware, USA) and Agilent RNA 6000 Nano Bioanalyzer (Agilent Technologies), respectively. RNA amplification and labeling of complementary RNA (cRNA) with Cy3 dye were performed using Agilent Low-Input QuickAmp Labeling kit according to the manufacturer's protocol. The Whole Human Genome 4x44K Oligomicroarray kit containing 41,193 probes (60-mer oligo DNA, including control probes) and Gene Expression Hybridization kit were used for the hybridization of labeled RNA. Scanning analysis was performed using the Agilent Microarray scanner and the acquired array images were processed using the Agilent Feature Extractions version 9.5. All the experimental protocols employed followed the manufacturer's protocol (Agilent Technologies).
Microarray data analysis. Microarray data generated by the feature extraction software were loaded in GeneSpring software, version 11.5 (Agilent Technologies). First, we normalized the microarray data across all chips and all genes using quantile normalization, and baseline transformed the signal values to the median in all samples. Then we performed quality control and filtering of the data by flags and by expression level. Entities with flag 'Detected' in at least one out of 18 samples and had values within the 20 and 100th percentiles in at least one out of 18 samples were retained for further analysis.
To identify genes that were differentially expressed among the three types of metastatic tissue, we grouped all five metastases in each of the three organs (bone, lung, liver), and then compared the fold change of expression in one group with the other pool of ten metastases in the other two organs, e.g. five bone metastases would be grouped as 'bone metastases', and compared with the group 'lung and liver metastases' that included five lung metastases and five liver metastases, and so on. We applied random permutation test 10,000 times for each comparison and adjusted for multiple comparison using the Benjamini-Hochberg false discovery rate (FDR). Gene expression level was considered significantly different when FDR was <0.05 (corrected P-value <0.05), and the fold change was at least 2.0 between groups. The output gene lists were further interpreted based on gene ontology analysis.
To rule out the cross-hybridization of normal mouse mRNA to human, we microdissected normal mouse cells from each organ, lung, liver and bone, and hybridized them on human DNA microarrays (Agilent) by the same method as described above. The contamination of mouse genes, if any, most likely had signal intensities above a certain cut-off value. We arbitrarily selected the 95th percentile value of the signal intensities value in metastasis in each organ as the cut-off value, and excluded those genes with signal intensity values higher than this cut-off value in the corresponding normal mouse tissues in each of these three organs.
For hierarchical cluster analysis, the normalized signal intensities of upregulated genes in each organ were subjected to Cluster 3.0 (14) , and clustered based on the centroid linkage. The output data were organized using TreeView 1.60 (15) . Data from this microarray experiment has been submitted to the NCBI Gene Expression Omnibus (GEO) archive as series GSE29391.
Reverse transcription and real-time RT-PCR. Total RNAs extracted from each of the microdissected tumor samples were reverse-transcribed by SuperScript II reverse-transcriptase (Invitrogen), asccording to the manufacturers protocol. We prepared appropriate dilutions of each single-stranded cDNA for subsequent PCR by monitoring the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a quantitative internal control. Quantitative PCR were performed using SYBR Premix Ex Taq (Takara) on Applied Biosciences Fast real-time 7500 system (Applied Biosciences). All the primers used in PCRs are listed in Table I 
Results
Evaluation of metastatic lesions in multi-organ metastasis model
. To obtain precise gene-expression profiles of 15 selected metastatic lesions (five in each organ: lung, liver, and bone) in a mouse model, we purified cancer cells from each organ by lasermicrobeam microdissection (see Materials and methods). The representative histopathological features of each of metastatic lesions in bone, lung and liver are shown in Fig. 1 . Consistent with previous results (13) , all mice developed metastases in bones as evaluation by overt clinical signs, sick mice showed limping due to fractures of hind limps, together with other signs such as weight loss, ruffling fur, dyspnea, big belly, but we collected osteolytic lesions in this microarray analysis because osteoblastic lesions were observed to a much lesser extent (~30%) (Fig. 1A) . We also observed metastatic lesions in lungs and livers of all mice (Fig. 1B and C) . Table I . Primers used in real-time RT-PCR.
Gene
Fordward primer (5'-3') Reverse primer (5'-3') Figure 1 . Histopathology of metastatic lesions in the bone (A), lung (B) and liver (C) (H&E staining). Tu, tumor tissue (dotted area, in some tumors there were necrotic and hemorrhagic regions); H, hepatocyte (normal tissue in liver); P, pneumocyte (normal tissue in lung); Bo, bone (dark area); Scale bars, 300 µm. Up-and downregulated gene expression profile of organselective metastases. To identify genes that were selectively expressed in each of the three metastatic organs, we performed the fold-change analysis in accordance with the following criteria: genes that were differentially expressed by at least two-fold with P<0.05 in one metastatic organ as compared to metastases in the other two organs. We identified a total of 299 genes, which were potentially involved in multi-organmetastasis features of lung cancer, including the upregulated genes in bone (77 genes), lung (106 genes) and liver (56 genes) metastases (Tables II-IV) . Moreover, a hierarchical clustering analysis of these 299 upregulated genes using Cluster and TreeView (14, 15) obviously separated the three-organ-specific groups of metastatic lesions ( Fig. 2A) . The genes preferentially expressed in bone metastases were shown as the focused view of the dendrogram (Fig. 2B) .
Validation of bone-preferentially expressed genes.
To validate the reliability of the expression data obtained by microarray analysis, we performed quantitative RT-PCR for eight genes that were preferentially overexpressed in bone metastasis. The results confirmed the microarray data in all of the tumors tested (Fig. 3) . Genes that were previously reported to be involved in bone metastasis or lung-carcinogenesis were identified in our results, including FGFR3, TTYH1, LEFTY1, TM4SF4, CRYM, FOLR1, METTL4 and GUCY1B3. The FGFR3 and TTYH1 genes are already reported to be associated with bone metastasis in breast cancers (16) . TM4SF4 and CRYM genes were reported as tumor markers in lung cancer (17) (18) (19) . FOLR1 gene was reported to be overexpressed in lung adenocarcinoma (20, 21) and has critical involvement in drug resistance (22) . METTL4 gene is known to be related to invasiveness and survival in lung cancer (23) , and GUCY1B3 gene was reported to be involved in osteoclast signaling pathway (24) . These findings suggest that those genes may potentially contribute to the bone-preferential metastasis of NSCLC cells.
Discussion
The molecular basis of organ tropism, one of the main characteristics of cancer metastasis, is still largely obscure. It has been documented that different types of cancer produce metastases at preferred secondary sites, depending on organ-susceptibility to specific cells. Stephen Paget proposed the 'seed and soil' theory that the molecular interactions between metastatic cells (seeds) and stromal microenvironment (soil) play critical roles throughout the multi-process of metastasis (25, 26) . In this study, we used a previously established multi-organ metastasis mouse model (13) , in which cancer cells were inoculated directly into the tail vein that travels to the lungs. Although the tumor cells can be trapped at the lungs as first capillary beds, there were also possibilities that the cells circulate systemically and can reach any organ. Therefore, the analysis of transcriptomic profiles of metastatic lesions in the three organs, bone, lung and liver, can lead to the identification of genetic changes in later steps of the metastasis cascade, when tumor cells have already homed to the specific organ. These changes also reflect the interaction between cancer cells and the local or host cells in the 'microenvironment' of the organ. To form metastatic tumors in a certain organ, cancer cells when homing to this specific organ must interact with the host microenvironment (25) (26) (27) . To do so, certain molecular programs in cancer cells are activated (25, 27) . Hence, to elucidate the specific changes of cancer cells in different metastatic organs, we performed microdissection to collect a pure population of cancer cells in metastatic lesions in each type of organ (three organs of five mice, totally 15 lesions), subsequently coupled with DNA microarray analysis. Hierarchical clustering analysis of the 299 organ preferentially expressed genes revealed that they seemed to reflect the organ selectivity of metastatic cells (Fig. 2) . In particular, we here focused on genes that were preferentially expressed in bonemetastases.
Among them, we demonstrated that the expression levels of FGFR3 and TTYH1 genes were significantly upregulated 
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in bone metastasis compared with metastasis in lung or liver. These genes have been previously reported to be upregulated in human breast cancer bone metastasis in clinical specimen (16) . Smid et al reported analysis of expression profiling in 107 human breast cancer patients who had relapse in bone or other sites in the body, and identified a panel of 69 genes that were upregulated in bone relapse, which included FGFR3 and TTYH1 (16) . FGFR3, encoding a receptor tyrosine kinase for fibroblast growth factor, was reported to be overexpressed in ~15-20% cases of myeloma, or constituvely activated due to mutations in most of bladder cancers and other solid tumors, including lung cancers. Fibroblast growth factors (FGF) are bone-derived factors abundant in the bone environment (6, 26) , therefore it is reasonable that lung cancer cells highly expressing FGFR3 might be more selectively colonized in bone than in lung or liver. In addition, the FGF-FGFR3 signaling pathway via Ras-MAPK and PI3K in cancer cells may lead to enhanced cell proliferation and migration (reviewed in refs. 28 and 29). TTYH1, an endoplasmic-localized protein, was reported to be a Ca 2+ -binding protein playing critical roles in mitosis and cell proliferation (30) . This molecule may therefore be essential for the cancer cells homing to the bone, and may contribute to the growth advantage of the metastatic tumors in the bone. LEFTY1 (also known as LEFTY-B), another promising target gene in the bone metastases profile, was confirmed to be significantly upregulated in bone metastasis. LEFTY1 was reported to be a secreted molecule of the TGF-β superfamily involved in the Nodal signaling pathway, and a marker of the stemness of cells (31-33), and to contribute to the remodeling process of the extracellular matrix (34) . In contrast, LEFTY1 also plays an important role as an inhibitor of Nodal, a crucial component involved in metastatic melanoma cells, in a negative feedback mechanism (reviewed in ref. 33) .
Recently, it was reported that cancer stem cells possess tumorigenic, invasive and migratory characteristics (25, 27) , and tumor cell plasticity (33) . These individual lines of evidence suggest that LEFTY1 may be involved in metastasis. Moreover, GUCY1B3, encoding an enzyme that catalyzes the conversion of GTP to cyclic GMP, is well-known to be involved in the pathway of nitride oxide signaling, which is one of the major post differentiation pathways in the osteoclast (24) . It is reported that the enhancement of a soluble form of GUCY1B3 led to the activation of the osteoclasts in the osteolytic bone metastasis process. Moreover, this protein enhances tumor growth of glioma (35) and angiogenesis in both glioma and chorioallantoic membrane (35, 36) , and plays paradoxical roles in the proliferation of cancer cells (37) , suggesting that GUCY1B3 could be involved in bone metastasis.
Furthermore, among the genes highly expressed in lung metastasis, we identified genes encoding surfactant protein C and D (SFTPC and SFTPD: 192-and 95-fold changes, respectively). Serum levels of SFTPC and SFTPD were previously reported to be elevated in mice with lung tumors (38, 39) . In humans, a research on lung adenocarcinoma showed the upregulation of SFTPC and SFTPD, especially SFTPD, in lymph node metastatic lesions (17 in 23 cases of metastases or micrometastases) (40) . Although specific role(s) of these molecules in lung metastasis are not characterized so far, our findings raise the possibilities that SFTPC and SFTPD proteins regulate the process of metastasis in general, or specifically, lung colonization, of the cancer cells in this multi-organ metastasis mouse model. Moreover, Claudin-18 (CLDN18), a tight junction molecule, was upregulated ~21-fold in lung metastases as compared with metastases in other organs. A recent immunotherapeutic strategy using auto-antibody against CLDN18 shows that the formation of pulmonary metastasis was significantly reduced in mice inoculated intravenously with colon cancer cells (41) , suggesting that CLDN18 could be a specific molecule for controlling metastasis, especially lung metastases. In addition, Dickkopf-1 (DKK1), a secreted protein that negatively regulates the Wnt signaling pathway, was upregulated 11-fold in lung metastases. It has been reported that DKK1 is a serologic and prognostic biomarker for lung cancers (42, 43) .
Finally, we focused on genes that were rank-ordered among genes that were preferentially expressed in liver metastasis, namely hemopexin (HPX) and vitronectin (VTN). HPX and VTN proteins belong to the hemopexin superfamily which includes matrix metalloproteinases (MMPs). HPX which is highly expressed in the liver binds to hemes and negates the toxic effect of hemes. It is remarkable that there are hundreds of proteins, including MMPs, containing one or several motifs that structurally and functionally resemble parts of the HPX protein (review in ref. 44 ). A latest report shows that small-molecule compounds that selectively target the hemopexin domain of MMP-9 can control tumor growth and inhibit lung metastasis in breast cancer xenograft model in mice (45) . Moreover, VTN, an extracellular protein that interacts with many integrins, is also expressed highly in the liver, and was previously reported to be upregulated in primary hepatocellular carcinoma (46) , or liver metastases from colorectal cancer (46, 47) and neuroblastoma (48) .
Thus, we identified a dozen potential metastasis-related molecules including other unknown functional molecules. However, relating to bone metastasis, there were no overlapping genes compared with previous report in SCLC (using SBC-5 cell line) (13) . This may reflect the fact that there are distinctive biologic processes involved in SCLC or NSCLC bone metastasis, although in both cases bone metastatic lesions were of same osteolytic phenotype. Vicent et al reported a lung cancer bone metastasis gene profile using NSCLC (NCI-H460, a large cell carcinoma cell line), by comparing the transcriptomes of the sublines possessing highly bone metastatic ability and the parental cell lines (12) . However, none of the genes in their data were identified in our bone metastasis gene profile. This discrepancy on microarray data may be due to several factors. In this study, we focused on lung cancer bone metastases from NSCLC (adenocarcinoma, ~60-70% of non-resectable NSCLC), not SCLC (4). In fact, SCLC consists of only ~15-20% of lung cancers, whereas NSCLC consists of 80-85%, and the natural course as well as the molecular basis of SCLC is quite distinct from NSCLC (2,4). The above evidence suggests that there were differences in the biology of bone metastases in NSCLC in comparison with SCLC.
In conclusion, through a human NSCLC cell line with enhanced bone metastasis ability in a multi-organ metastasis mouse model coupled with microarray analysis, we identified dozens of genes which were potentially involved in metastases to the bone, lung, and liver. However, it will be necessary to perform further functional analyses using gain-or loss-offunction approaches in mouse models and validation in human clinical samples. Our findings should be helpful for better understanding of molecular aspects of the metastatic process in different microenvironments, especially in bone metastases, and could lead to molecular target-based anticancer drugs and prevention of metastasis.
